Goldman Sachs agreed to acquire an 8% stake in Karuna Therapeutics, a clinical-stage biopharmaceutical company, from PureTech Health, a clinical stage biotechnology company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, for $200m. "As a founder of Karuna and co-inventor of the KarXT program, we are delighted to continue to be a major shareholder of Karuna going forward. With multiple efficacy studies validating both xanomeline and KarXT, Karuna is well-positioned to be a major player in the neuropsychiatry field. We are particularly enthusiastic about the potential for patients to have a new and differentiated treatment option for schizophrenia and related diseases. This is an area that - despite a large market where branded therapies have been blockbuster products - has been lacking innovation for decades. We have a high degree of confidence in the team, who have an impressive track record, to unlock the full potential of the growth opportunities that may be available to them," Daphne Zohar, PureTech Founder and CEO.